Cresco Labs
Market Cap
CA$540.8m
Last Updated
2019/10/14 03:24 UTC
Data Sources
Company Financials +
Executive Summary
Cresco Labs Inc. cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States.
Snowflake
Fundamentals
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Cresco Labs's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.4%
CL
-11.0%
CA Pharmaceuticals
-0.4%
CA Market
1 Year Return
n/a
CL
-61.9%
CA Pharmaceuticals
0.9%
CA Market
Return vs Industry: Insufficient data to determine how CL performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CL performed against the Canadian Market.
Share holder returns
| CL | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.4% | -11.0% | -0.4% |
| 30 Day | -24.7% | -26.9% | -2.1% |
| 90 Day | -34.6% | -35.5% | -1.5% |
| 1 Year | n/a | -62.2%-61.9% | 4.4%0.9% |
| 3 Year | n/a | 84.6%83.3% | 15.7%5.4% |
| 5 Year | n/a | 269.8%269.8% | 26.1%7.9% |
Price Volatility Vs. Market
How volatile is Cresco Labs's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Who Has Been Selling Cresco Labs Inc. (CNSX:CL) Shares?4 months ago | Simply Wall St
Have Insiders Been Selling Cresco Labs Inc. (CNSX:CL) Shares?9 months ago | Simply Wall St
Should You Be Concerned About Cresco Labs Inc.'s (CNSX:CL) ROE?Valuation
Is Cresco Labs undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Undervalued: CL (CA$7.91) is trading below our estimate of fair value (CA$382.4)
Significantly Undervalued: CL is trading below fair value by more than 20%.
Price Based on Earnings
PE vs Industry: CL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: CL is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price Based on Expected Growth
Low PEG Ratio: Insufficient data to calculate CL's PEG Ratio to determine if it is good value.
Price Based on Value of Assets
PB vs Industry: CL is overvalued based on its PB Ratio (2.5x) compared to the CA Pharmaceuticals industry average (1.9x).
Next Steps
Future Growth
How is Cresco Labs expected to perform in the next 1 to 3 years based on estimates from 9 analysts?
183.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Earnings vs Savings Rate: CL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CL's revenue (86.3% per year) is forecast to grow faster than the Canadian market (5.7% per year).
High Growth Revenue: CL's revenue (86.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Estimates
Future Return on Equity
High Future ROE: CL's Return on Equity is forecast to be low in 3 years time (6%).
Next Steps
Past Performance
How has Cresco Labs performed over the past 5 years?
-1131.1%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CL is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.
Accelerating Growth: Unable to compare CL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: CL has a negative Return on Equity (-5.39%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: CL is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: CL is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Cresco Labs's financial position?
Financial Position Analysis
Short Term Liabilities: CL's short term assets (CA$160.2M) exceeds its short term liabilities (CA$31.5M)
Long Term Liabilities: CL's short term assets (CA$160.2M) exceeds its long term liabilities (CA$51.2M)
Debt to Equity History and Analysis
Debt Level: CL is debt free.
Reducing Debt: CL had no debt 5 years ago.
Balance Sheet
Inventory Level: CL has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CL's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Cresco Labs's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Dividend Yield and Payments Analysis
Notable Dividend: Unable to evaluate CL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Cresco Labs's salary, the management and board of directors tenure and is there insider trading?
0.9yrs
Average board tenure
CEO
Charlie Bachtell (41yo)
0yrs
Tenure
Mr. Charles Bachtell, also known as Charlie, serves as Co-Founder and Chief Executive Officer at Cresco Labs, LLC and has been its Director since November 30, 2018. He served as an Executive Vice President ...
Board Age and Tenure
0.9yrs
Average Tenure
51yo
Average Age
Experienced Board: CL's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: CL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 16,200 |
| Max Price | US$8.26 |
| Entity | Individual |
| Shares | 330 |
| Max Price | US$6.04 |
| Entity | Individual |
| Role | Vice Chairman Co-Founder & Vice-Chairman |
| Shares | 14,000 |
| Max Price | US$6.79 |
| Entity | Individual |
| Shares | 1,554 |
| Max Price | US$6.71 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 10,000 |
| Max Price | US$9.72 |
| Entity | Individual |
| Shares | 3,000 |
| Max Price | US$7.33 |
| Entity | Company |
| Shares | 7,750 |
| Max Price | US$12.94 |
| Entity | Individual |
| Role | Chief Operating Officer Chief Operating Officer |
| Shares | 6,500 |
| Max Price | US$9.15 |
| Entity | Individual |
| Role | Chief Operating Officer Chief Operating Officer |
| Shares | 6,500 |
| Max Price | US$5.25 |
Ownership Breakdown
Management Team
Rob Sampson (45yo)
Co-Founder & Director
- Tenure: 0.9yrs
Charlie Bachtell (41yo)
Co-Founder
- Tenure: 0yrs
Dominic Sergi (36yo)
Co-Founder & Director
- Tenure: 0.9yrs
Brian McCormack (51yo)
Co-Founder & Vice-Chairman
- Tenure: 0yrs
Joe Caltabiano (42yo)
President
- Tenure: 0.9yrs
Ken Amann (48yo)
Chief Financial Officer
- Tenure: 0yrs
David Ellis (37yo)
Chief Operating Officer
- Tenure: 0yrs
John Schetz (42yo)
General Counsel
- Tenure: 0.9yrs
Aaron Miles
Vice President of Investor Relations
- Tenure: 0yrs
Mo Dastagir
Chief Information Officer
- Tenure: 0.3yrs
Board Members
John Walter (72yo)
Director
- Tenure: 2.5yrs
Gerry Corcoran (64yo)
Director
- Tenure: 2.5yrs
Tom Manning (63yo)
Chairman
- Tenure: 0.8yrs
Rob Sampson (45yo)
Co-Founder & Director
- Tenure: 0.9yrs
Charlie Bachtell (41yo)
Co-Founder
- Tenure: 0yrs
Dominic Sergi (36yo)
Co-Founder & Director
- Tenure: 0.9yrs
Brian McCormack (51yo)
Co-Founder & Vice-Chairman
- Tenure: 0yrs
Randy Podolsky (64yo)
Director
- Tenure: 0.9yrs
Joe Caltabiano (42yo)
President
- Tenure: 0.9yrs
Company Information
Cresco Labs Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cresco Labs Inc.
- Ticker: CL
- Exchange: CNSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$540.840m
- Shares outstanding: 68.37m
- Website: https://www.crescolabs.com
Number of Employees
Location
- Cresco Labs Inc.
- 400 West Erie Street
- Suite 110
- Chicago
- Illinois
- 60654
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CL | CNSX (Canadian National Stock Exchange) | Yes | Subordinate Voting Shares | CA | CAD | Dec 2018 |
| CRLB.F | OTCPK (Pink Sheets LLC) | Yes | Subordinate Voting Shares | US | USD | Dec 2018 |
| 6CQ | DB (Deutsche Boerse AG) | Yes | Subordinate Voting Shares | DE | EUR | Dec 2018 |
Biography
Cresco Labs Inc. cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flower, vape pens, and various forms of extracts under the cr ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 03:24 |
| End of Day Share Price | 2019/10/11 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.